Botulinum Toxin Type A
Brand Names: Daxxify, Dysport
Methodology & AI Transparency ⓘ
Botulinum Toxin Type A Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage daxxify: is an acetylcholine release inhibitor and neuromuscular-blocking agent indicated for: Temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/ or procerus muscle activity in adult patients.
- 2 Real-world patient consensus: 77% patient "Worth It" rating across 5 anonymous logs for Botulinum Toxin Type A (RxNorm 2612454).
- 3 Typical cash cost range: 30-day cash pricing ranges from $33.61 discount cash to $82.34 walk-in retail (NADAC $0.6200/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Botulinum Toxin Type A): headache (6%), nausea (7.3%), dizziness (6.4%).
Ask our AI Specialists anything about Botulinum Toxin Type A
Botulinum Toxin Type A Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage daxxify: is an acetylcholine release inhibitor and neuromuscular-blocking agent indicated for: Temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/ or procerus muscle activity in adult patients. ( 1.1 ) The treatment of cervical dystonia in adult patients. ( 1.2 ) 1.1 Glabellar Lines DAXXIFY is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
12.1 Mechanism of Action DAXXIFY blocks neuromuscular transmission at the neuromuscular junction by inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein necessary for the successful docking and release of acetylcholine vesicles within nerve endings. Recovery of neurotransmission occurs gradually as the neuromuscular junction recovers from SNAP-25 cleavage and as new nerve endings are formed.
Clinical clearance of Botulinum Toxin Type A (Acetylcholine Release Inhibitor) relies on phase i/ii hepatic conjugation of botulinum toxin type a coupled with glomerular and tubular renal excretion with a Approximately 3–7 hours terminal plasma half-life for Botulinum Toxin Type A half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Botulinum Toxin Type A (500 U/1 Injection, Powder, Lyophilized, for Solution) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after botulinum toxin type a administration.
FDA clinical labeling for Botulinum Toxin Type A restricts administration in the presence of infection at the proposed injection sites.; known hypersensitivity to botulinum toxin type a or structurally related acetylcholine release inhibitor compounds across 500 U/1 Injection, Powder, Lyophilized, for Solution, 300 U/1 Injection, Powder, Lyophilized, for Solution, 100 U/1.2mL Injection, Powder, Lyophilized, for Solution, with self-reported patient tracking dominated by nausea (7.3% of reports), dizziness (6.4% of reports), headache (6% of reports).
Avoid overlapping acetylcholine release inhibitor prescriptions alongside Botulinum Toxin Type A to prevent cumulative receptor toxicity.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Botulinum Toxin Type A dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- the presence of infection at the proposed injection sites.
- Known hypersensitivity to Botulinum Toxin Type A or structurally related acetylcholine release inhibitor compounds
Logged Side-Effect Incidence (5 Reports)
Botulinum Toxin Type A Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Botulinum Toxin Type A)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on LetibotulinumtoxinA Attenuates the Psychological Burden of Glabellar Lines and Is: What a 1,272-Participant Study Found LetibotulinumtoxinA significantly improved the psychosocial burden associated with glabellar lines across all trials. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] • 2024-06-01 • Phase III Randomized Trial | N = 1,272 | 96/100 | PMID 38470985 ↗ |
| New Insights on Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development,: What a 5,000-Participant Study Found Benefits also include improvements in quality of life, fewer psychiatric comorbidities, and reduced healthcare resource utilization. Medicine • 2023-07-01 • Phase III Randomized Trial | N = 5,000 | 96/100 | PMID 37499085 ↗ |
| Check Your Medicine Cabinet: HAIFA SMOKED FISH Recalls Cold Smoked Sprats Due to Potential Health Risk HAIFA SMOKED FISH of QUEENS NY is recalling approximately 560 lbs. of Cold Smoked Sprats, due to potential contamination with Clostridium botulinum, a bacterium which can cause life-threatening illness. Consumers are warned not to use the product even if it do FDA Drug Recalls • 2026-10-27 • FDA Recall | Multi-cohort | 95/100 | PMID FDA_RECALLS-1160800238 ↗ |
| New Insights on Phase I/III Clinical Trial to Evaluate the safety and real-world benefits of a: What a 290-Participant Study Found HU-014 has noninferior real-world benefits and safety compared with onabotulinumtoxinA in the treatment of CFL. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] • 2021-04-01 • Phase III Randomized Trial | N = 290 | 93/100 | PMID 33795571 ↗ |
| New Insights on Benefits and safety of CKDB-501A in Treating Moderate-To-Severe Glabellar Lines:: What a 300-Participant Study Found CKDB-501A is a safe and effective alternative to existing botulinum toxin products for treating moderate-to-severe glabellar lines, offering benefits of improved biocompatibility and reduced risk of allergic reactions. Journal of cosmetic dermatology • 2025-07-15 • Phase III Randomized Trial | N = 300 | 93/100 | PMID 40586136 ↗ |
Botulinum Toxin Type A Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.6200/unit (~$18.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $82.34 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 5 Anonymous DotMD Community Micro-Logs | $33.61 / mo | View logs ↓ |
Botulinum Toxin Type A Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Botulinum Toxin Type A RxNorm Concept ID | 2612454 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.6200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $82.34 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $33.61 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 77.00% Worth It (5 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Botulinum Toxin Type A Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Botulinum Toxin Type A: FDA labeling (2026-01-07, NDC 72960-112), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Botulinum Toxin Type A community threads and patient logs by age, biological sex, dosage, and treatment duration.